Steady-State Pharmacokinetics of Roflumilast and Roflumilast N -Oxide in Patients with Mild and Moderate Liver Cirrhosis

By Hermann Robert  

Clinical Pharmacokinetics, Vol. 46, Iss. 5, 2007-01 ,pp. : 403-416

Adis International

Access to resources Recommend Favorite

Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model

By Lahu Gezim   Hünnemeyer Andreas  

Clinical Pharmacokinetics, Vol. 49, Iss. 9, 2010-09 ,pp. : 589-606

Adis International

Access to resources Recommend Favorite

Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects

By Huennemeyer Andreas   Nassr Nassr   Bredenbrööker Dirk   Lahu Gezim  

Expert Opinion on Drug Safety, Vol. 10, Iss. 4, 2011-07 ,pp. : 509-519

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of roflumilast

By Lahu Gezim   Nassr Nassr   Hünnemeyer Andreas  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 12, 2011-12 ,pp. : 1577-1591

Informa Healthcare

Access to resources Recommend Favorite

Reminder of roflumilast psychiatric ADRs

By  

Reactions Weekly, Vol. 1, Iss. 1386, 2012-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite